Phase I/II of Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma.
Phase of Trial: Phase I/II
Latest Information Update: 31 Oct 2014
At a glance
- Drugs Everolimus (Primary) ; Panobinostat (Primary)
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 01 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrial.gov record.
- 26 Feb 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrial.gov record.
- 21 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.